Save time and get answers to complex questions with AI chat
Patent expiration eu dabrafenib?Defense strategy against generic in niche market?When will a generic version of xiaflex be available?When will generic fiasap insulin be available?Quartette side effects?
See the DrugPatentWatch profile for kisqali
Short answer: No new Kisqali (ribociclib) approval for early breast cancer was issued in September 2024. The adjuvant (early breast cancer) indication was approved earlier, in March 2023, for HR+/HER2− high-risk disease in combination with an aromatase inhibitor. If you want the exact FDA press release date for that adjuvant approval, I can look it up. Also, I can provide dosing, safety notes, or label details if you’d like.
Other Questions About Kisqali :